International immunopharmacology · 2025
Elabela APJ Axis attenuates type II diabetes osteoporosis by enhancing the coupling of H-type angiogenesis and osteogenesis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ma Run-Xun, Guo Yang-Fan, Feng Si-Xiang, Huang Yi-Xun, Pan Li-Bo, Bu Yi-Tian, Wang Yi-Kai, Luo Jian, Lin Bing-Hao, Yang Lei
Аннотация
BACKGROUND: Type 2 diabetes-related osteoporosis (T2DOP) is intricately connected to microvascular degeneration, particularly the loss of H-type vessels involved in osteogenesis-angiogenesis coupling. Elabela (ELA), a crucial APJ receptor ligand, regulates vascular development, yet its specific role in the diabetic bone microenvironment remains undefined. This study investigates whether ELA restoring H-type vessel formation and vascular-bone coupling offers a therapeutic strategy for T2DOP.
METHODS: A T2DOP mouse model was established using a high-fat diet combined with low-dose streptozotocin (STZ) injection. Bone microarchitecture and vasculature were assessed via micro-CT and immunofluorescence. In vitro, bone marrow endothelial cells (BMECs) were subjected to high-glucose and high-fat (HGHF) stress and co-cultured with MC3T3-E1 osteoblasts in a Transwell system to evaluate vascular-bone coupling. The role of the ELA-APJ axis was interrogated using exogenous ELA peptide (1 mg/kg/day in vivo; 5 μM in vitro) and the specific APJ inhibitor ML221.
RESULTS: T2DOP mice exhibited significantly reduced femoral H-type vessel density and downregulated ELA expression compared to controls. ELA administration significantly reversed bone loss, increasing bone volume fraction (BV/TV) by 10.3 % ((p < 0.01))and trabecular number (Tb.N) by 1.8/mm (p < 0.05). Mechanistically, ELA treatment rescued HGHF-impaired BMEC migration and tube formation In the co-culture system, ELA-stimulated BMECs enhanced osteogenic differentiation in MC3T3-E1 cells, indicated by elevated ALP activity and mineralization. Critically, these protective effects were abolished by the APJ inhibitor ML221, confirming that ELA activates the HIF-1α/VEGF/Notch1/Noggin signaling cascade to restore angiocrine function.
CONCLUSION: The ELA/APJ axis is a critical regulator of the bone vascular niche. ELA treatment attenuates T2DOP by promoting H-type vessel formation and re-coupling osteogenes.
METHODS: A T2DOP mouse model was established using a high-fat diet combined with low-dose streptozotocin (STZ) injection. Bone microarchitecture and vasculature were assessed via micro-CT and immunofluorescence. In vitro, bone marrow endothelial cells (BMECs) were subjected to high-glucose and high-fat (HGHF) stress and co-cultured with MC3T3-E1 osteoblasts in a Transwell system to evaluate vascular-bone coupling. The role of the ELA-APJ axis was interrogated using exogenous ELA peptide (1 mg/kg/day in vivo; 5 μM in vitro) and the specific APJ inhibitor ML221.
RESULTS: T2DOP mice exhibited significantly reduced femoral H-type vessel density and downregulated ELA expression compared to controls. ELA administration significantly reversed bone loss, increasing bone volume fraction (BV/TV) by 10.3 % ((p < 0.01))and trabecular number (Tb.N) by 1.8/mm (p < 0.05). Mechanistically, ELA treatment rescued HGHF-impaired BMEC migration and tube formation In the co-culture system, ELA-stimulated BMECs enhanced osteogenic differentiation in MC3T3-E1 cells, indicated by elevated ALP activity and mineralization. Critically, these protective effects were abolished by the APJ inhibitor ML221, confirming that ELA activates the HIF-1α/VEGF/Notch1/Noggin signaling cascade to restore angiocrine function.
CONCLUSION: The ELA/APJ axis is a critical regulator of the bone vascular niche. ELA treatment attenuates T2DOP by promoting H-type vessel formation and re-coupling osteogenes.